Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Strand

Showing results (471-480 of 499) with videos related to

Pageof 50
Sort By:
The Science of the Total Environment|December 13, 2022
Tradeoffs and synergies in wetland multifunctionality: A scaling issueP A Hambäck, L Dawson, P Geranmayeh, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2016
Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activationPeter M Grace, Keith A Strand, Erika L Galer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) InfectionJeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Neuroscience|September 22, 2014
Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelaeP M Grace, K M Ramos, K M Rodgers, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanomaTina J Hieken, David Zahrieh, Thomas J Flotte, et al.
Brain : a Journal of Neurology|June 15, 2019
Progressive agrammatic aphasia without apraxia of speech as a distinct syndromeKaterina A Tetzloff, Joseph R Duffy, Heather M Clark, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 4, 2026
Randomized, Double-blind, Placebo-controlled Trial of Meriva® (curcuminoids) as a Candidate Chemoprevention Agent for Gastric CarcinogenesisMaria Gonzalez-Pons, Ricardo L Dominguez, Eleazar E Montalvan-Sanchez, et al.
Annals of Neurology|December 4, 2020
Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia PhenotypeMarina Buciuc, Jennifer L Whitwell, Koji Kasanuki, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Pageof 50

Showing results (471-480 of 499) with videos related to

Sort By:
Pageof 50
The Science of the Total Environment|December 13, 2022
Tradeoffs and synergies in wetland multifunctionality: A scaling issueP A Hambäck, L Dawson, P Geranmayeh, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 2, 2016
Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activationPeter M Grace, Keith A Strand, Erika L Galer, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 19, 2022
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) InfectionJeffrey M Jacobson, David Zahrieh, Carrie A Strand, et al.
Neuroscience|September 22, 2014
Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelaeP M Grace, K M Ramos, K M Rodgers, et al.
European Journal of Cancer (Oxford, England : 1990)|August 12, 2025
NeoACTIVATE Arm C: Phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable Stage III melanomaTina J Hieken, David Zahrieh, Thomas J Flotte, et al.
Brain : a Journal of Neurology|June 15, 2019
Progressive agrammatic aphasia without apraxia of speech as a distinct syndromeKaterina A Tetzloff, Joseph R Duffy, Heather M Clark, et al.
Cancer Prevention Research (Philadelphia, Pa.)|May 4, 2026
Randomized, Double-blind, Placebo-controlled Trial of Meriva® (curcuminoids) as a Candidate Chemoprevention Agent for Gastric CarcinogenesisMaria Gonzalez-Pons, Ricardo L Dominguez, Eleazar E Montalvan-Sanchez, et al.
Annals of Neurology|December 4, 2020
Lewy Body Disease is a Contributor to Logopenic Progressive Aphasia PhenotypeMarina Buciuc, Jennifer L Whitwell, Koji Kasanuki, et al.
Journal for Immunotherapy of Cancer|April 15, 2025
Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trialMatthew S Block, Garth D Nelson, Jun Chen, et al.
Frontiers in Immunology|November 29, 2023
A phase I oncolytic virus trial with vesicular stomatitis virus expressing human interferon beta and tyrosinase related protein 1 administered intratumorally and intravenously in uveal melanoma: safety, efficacy, and T cell responsesKatherine E R Smith, Kah-Whye Peng, Jose S Pulido, et al.
Pageof 50